2025 Greenwall Faculty Scholars in Bioethics
No Applicants // Limit: 1 // Tickets Available: 1
Limiting Language
No Applicants // Limit: 1 // Tickets Available: 1
Limiting Language
No Applicants // Limit: 1 // Tickets Available: 1
Limiting Language
Applicants are only allowed to submit one proposal per organization. If more than one proposal is submitted from an organization, all proposals from that institution will be considered ineligible for funding.
Executive Summary
Priority Region: Jordan
Dear colleagues,
I am pleased to announce the appointment of Dr. Krishna Muralidharan as Director of the Center for Semiconductor Manufacturing. After serving effectively as interim director, Dr. Muralidharan has already set a strong foundation for CSM’s continued growth and relevance in one of our nation’s most strategically important industries.
The Comprehensive Center for Pain and Addiction addresses chronic pain and substance use disorders by combining research, clinical care, education, policy and technology to expand access to nonopioid treatments, advance clinical trials and engage communities.
The Center for Sleep and Circadian Sciences studies how sleep and biological rhythms affect health and disease, using controlled human studies and imaging to inform interventions that range from gene-level discovery to public safety.
CIBS drives therapeutic development for Alzheimer’s, Parkinson’s, Multiple Sclerosis and ALS by linking basic discovery to clinical application through precision medicine, data science and patient-centered research.
Limit: 1 // Tickets Available: 0
H. Wilson (Cooperative Extension)
Limiting Language
Each organization can submit one standalone application. The grants portal tracks this by EIN number, hence each EIN number can only appear once in the grant cycle.
Background
CB2 supports health sciences research with expertise in data science, informatics and biostatistics, offering training and consultation while advancing solutions that promote health equity and benefit underserved communities.
CAMI develops next-generation immunotherapies and molecular treatments for cancer, autoimmune disorders and infectious diseases by accelerating discovery, commercialization and biomedical workforce training.
No Applicants // Limit: 1 // Tickets Available: 1
Limiting Language
An applicant may submit only one application in response to the NOFO. An entity may be proposed as a subrecipient in more than one application. Applications under which two or more entities (project partners) would carry out the federal award will be considered. However, only one entity may be the applicant for the NOFO; any others must be proposed as subrecipients. See the Application Resource Guide for additional information on subawards.